HomeAI · summaries
Storia in 2 fonti
Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China
Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor to Genentech’s eye drug Vabysmo.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over…
- ·
endpoints.news
Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China
Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor to Genentech’s eye drug Vabysmo.